Pay in 4 interest-free payments of $5.46 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Explore the rest of our copper peptide skin care range, including face, neck, and scalp formulations
AOD-9604 Adolescent (12 to 17) Dosing: What Clinicians and Parents Need to Know At a glance Regulatory status / No FDA approval for any indication or age group Typical research dose in adults / 250 to 500 mcg subcutaneous once daily (not validated in adolescents) Adolescent trial evidence / Zero published RCTs in the 12, 17 age group Key safety concern / Potential interference with growth-plate biology and pubertal GH axis Compounding status / Available only through 503A compounding pharmacies under prescriber order Primary preclinical evidence / Heffernan et al
Is AOD 9604 FDA-approved
Monitoring and Documentation Considerations For research contexts where cagrilintide dosage with retatrutide protocols might be explored under appropriate oversight, comprehensive monitoring becomes absolutely essential: Suggested Monitoring Parameters: Weekly weight and body composition measurements Gastrointestinal symptom logs (nausea severity scales, vomiting frequency, bowel patterns) Nutritional intake tracking to ensure adequate caloric and nutrient consumption Hydration status assessment Vital signs including heart rate and blood pressure Laboratory markers (glucose, lipids, liver function, kidney function) Subjective well-being assessments This level of monitoring exceeds what's typically required for single-agent protocols but reflects the increased uncertainty surrounding combination approaches without clinical trial data
But unless you have a B12 deficiency, theres really no role for it, Sukol says of B12 shots and supplements
